Zynerba Press Releases

28 Sep 17
Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X Syndrome

6 Sep 17
Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences

14 Aug 17
Zynerba Pharmaceuticals Announces that Results from Phase 2 STOP Trial Support Continued Development of ZYN002 in Osteoarthritis

7 Aug 17
Zynerba Pharmaceuticals Announces Top-Line Results from Phase 2 STAR 1 Trial of ZYN002 in Adult Epilepsy Patients with Focal Seizures

1 Aug 17
Zynerba Pharmaceuticals Reports Second Quarter 2017 Financial Results and Operational Highlights

28 Jul 17
Zynerba Pharmaceuticals Mourns Passing of Director Cynthia A. Rask

26 Jun 17
Zynerba Pharmaceuticals Added to the Russell 3000® Index

26 Jun 17
Zynerba Pharmaceuticals Initiates ZYN001 Phase 1 Clinical Program

8 Jun 17
Zynerba Pharmaceuticals Achieves Target Enrollment in Exploratory Phase 2 Trial of ZYN002 in Fragile X Syndrome

1 Jun 17
Zynerba Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference